Correlations between lipid profiles and atherosclerotic plaque characteristics in adult patients with type 2 diabetes mellitus

2型糖尿病成人患者血脂谱与动脉粥样硬化斑块特征的相关性

阅读:1

Abstract

BACKGROUND AND PURPOSE: Diabetes mellitus and dyslipidemia are major risk factors for atherosclerosis. Hypoechoic plaques, which indicate vulnerable or unstable plaques, may rupture and lead to ischemic stroke, cognitive impairment, increased adverse cardiac events, and even death. This study aimed to investigate the correlation between plasma lipid levels and the characteristics of atherosclerotic plaques in adult patients with type 2 diabetes mellitus. METHODS: A retrospective analysis was conducted on adult patients with type 2 mellitus who were hospitalized in the Department of Endocrinology at Affiliated Hospital of Hebei University between January 2017 and December 2021.Patients were categorized into two groups based on arterial ultrasound results. Statistical analyses were performed to compare plasma lipid levels and plaque characteristics across the groups. RESULTS: 1) Statistically significant differences were observed among the two groups in terms of gender, hypertension, age, duration of diabetes mellitus, plaque location, triglycerides (TG),total cholesterol (TC), Apolipoprotein A1 (Apo A1),very-low-density lipoprotein (VLDL), VLDL/apolipoprotein B(ApoB), high-density lipoprotein cholesterol (HDL)/ApoA1 (P<0.05). 2) Univariate and multivariate regression analyses revealed that VLDL,VLDL/ApoB and HDL/ApoA1 were correlated with plaque stability, the higher the levels of VLDL,VLDL/ApoB and HDL/ApoA1,the more likely they were to be hypoechoic plaque group (OR>1, P<0.05). 3) VLDL, VLDL/ApoB and HDL/ApoA1 showed predictive value for determining whether patients with type 2 diabetes had stable plaques. The area under the receiver operating characteristic (ROC) curve for VLDL, VLDL/ApoB and HDL/ApoA1 respectively were 0.789,0.779 and 0.728. CONCLUSION: In clinical practice, the characteristics of atherosclerotic plaques and lipid profiles should be jointly evaluated to guide targeted treatment and effectively reduce the risk of atherosclerotic cardiovascular disease.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。